Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 50Lung Neoplasms 13Neoplasms 8Melanoma 6Neoplasm Metastasis 5Head and Neck Neoplasms 5Squamous Cell Carcinoma of Head and Neck 4Breast Neoplasms 4Urinary Bladder Neoplasms 3Triple Negative Breast Neoplasms 3Stomach Neoplasms 3Ovarian Neoplasms 3Colorectal Neoplasms 3Carcinoma, Merkel Cell 3Carcinoma, Hepatocellular 3Uterine Cervical Neoplasms 2Prostatic Neoplasms 2Pancreatic Neoplasms 2Mesothelioma, Malignant 2Gastrointestinal Neoplasms 2Colonic Neoplasms 2Carcinoma, Squamous Cell 2Carcinoma, Renal Cell 2Carcinoma, Large Cell 2Carcinoma, Basal Cell 2Brain Neoplasms 2Advanced Non-Small Cell Lung Cancer 2Adenocarcinoma 2Vaccinia 1Uterine Neoplasms 1

Interventions

sotorasib 1pembrolizumab 1lorlatinib 1liposomal doxorubicin 1encorafenib 1cemiplimab 1binimetinib 1berzosertib 1Topotecan 1Taxes 1Paclitaxel 1PX-866 1NVP-BKM120 1Lomustine 1Irinotecan 1Gemcitabine 1Everolimus 1Doxorubicin 1Docetaxel 1Cetuximab 1Carboplatin 1Albumin-Bound Paclitaxel 13-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hereditary Sensory and Autonomic Neuropathies × cemiplimab × Thoracic × Clear all
NCT05882734 2026-05-28

Tuvusertib (M1774) in Combination With Cemiplimab in Participants With Non-Squamous NSCLC (DDRiver NSCLC 322)

EMD Serono

Phase 1/2 Active not recruiting
61 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Hereditary Sensory and Autonomic Neuropathies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡